Your zip code is more predictive than your BMI for whether Medicaid will cover Wegovy.

Published May 25, 2026 · Epioneum editorial · ~7 minute read

In Virginia, an adult on Medicaid with a BMI of 32 and one weight-related comorbidity can fill Wegovy with a prior authorization that clears in roughly two weeks. The same patient, same federal program, moves to Florida and the answer is no. The denial is not about the patient’s medical situation. It is about which state legislature voted what in which budget year, and how much money was left over for pharmacy.

Medicare won’t pay for weight loss. The 2003 law that decided this is older than Wegovy.

The Medicare Modernization Act of 2003 created Medicare Part D, the prescription drug benefit. The same law explicitly excluded coverage of “agents when used for anorexia, weight loss, or weight gain.” That clause was inserted as cost containment in 2003. Semaglutide would not get FDA approval until 2017. Wegovy would not get its weight-loss indication until 2021.

Medicare’s no-weight-loss-drugs rule predates the drugs by almost two decades.

The wedge that opened in 2024: the FDA expanded Wegovy’s label to include reduction of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher. CMS clarified in March 2024 that Part D plans could cover Wegovy when prescribed for the cardiovascular indication, not for weight loss alone. Same drug, same dose, different ICD-10 code, different coverage outcome.

The proposed Biden-era CMS rule in November 2024 to broadly expand anti-obesity medication coverage under Medicare and Medicaid was not finalized. On April 4, 2025, CMS announced it would not include Medicare Part D coverage of anti-obesity medications in the CY2026 final rule, citing Executive Order 14192. The agency left open the possibility of revisiting the question in future rulemaking but did not commit to a timeline.

About 13 state Medicaid programs cover GLP-1 for obesity. The list moves.

The Medicaid pattern is the most consequential layer for low-income Americans. Per KFF’s January 2026 update, 13 state Medicaid programs include GLP-1 medications on formulary for obesity treatment, down from 16 the previous October as California, New Hampshire, Pennsylvania, and South Carolina dropped coverage, and as North Carolina dropped coverage in October 2025 and reinstated it in December. This is in addition to the broader coverage all states provide for type 2 diabetes.

The 13 currently covering, as of January 2026: Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, and Washington. Texas, Florida, Georgia, Tennessee, Alabama, Mississippi, and most other Southern states do not. Pennsylvania and California, two of the largest Medicaid populations covering as recently as mid-2025, are no longer on the list. Expect this list to keep shifting — usually each state fiscal year, sometimes mid-year if pharmacy budgets exceed projection.

The distinction in the law is sharp. Type 2 diabetes makes Ozempic, Mounjaro, and similar molecules a covered benefit in every state Medicaid program. Obesity, even with severe BMI and documented comorbidities, makes the same molecules an optional coverage decision the state can either pick up or decline.

Prior authorization patterns where coverage exists are stringent. Typical requirements: BMI of 30 or higher, or 27 with documented comorbidity. Documented prior attempts at lifestyle modification, often six months of structured behavioral intervention. Monthly weight check-ins to maintain coverage. Some states layer in additional step therapy through phentermine or orlistat first.

North Carolina covered. Then North Carolina did the math.

The clearest case study sits inside state employee plans, not Medicaid. The North Carolina State Health Plan, which covers around 750,000 state employees and dependents, added GLP-1 coverage for obesity in 2022.

By the time of the vote in January 2024, more than 23,000 plan members were on GLP-1 medications at a net cost above $800 per member per month after rebates, with plan spending projected to exceed $170 million in 2024 alone and more than $1 billion over the following six years. Plan trustees voted 4-3 on January 25, 2024 to drop obesity coverage for these medications. The cutoff took effect April 1, 2024. Diabetes coverage stayed in place. Obesity-indication coverage was removed.

The math that drove the decision is the math every state Medicaid director is doing now. List price of Wegovy is around $1,350 a month, with current net price after rebates running roughly $6,800 a year for injectable semaglutide and around $7,900 a year for tirzepatide per the Institute for Clinical and Economic Review’s revised evidence report. ICER found both drugs cost-effective at conventional per-patient thresholds and set a health-benefit price benchmark of $9,100 to $12,500 a year for injectable semaglutide and $11,700 to $16,100 a year for tirzepatide. The contradiction is the budget. Drugs that are cost-effective on a per-patient basis still consume a quarter of an entire state pharmacy budget at population scale, because the eligible population is so large. ICER’s own analysis flagged that fewer than 1% of eligible US adults can currently afford GLP-1 treatments at net price.

The cost trajectory is what is forcing the patchwork. Drugs that genuinely work for a condition that genuinely affects roughly 40% of US adults create a fiscal collision with how every public insurance program is funded.

Your commercial insurer answers to your employer’s formulary, not your doctor.

The third layer is employer-sponsored coverage, where roughly half of all US adults get their insurance.

A commercial insurance card is misleading shorthand. The same Blue Cross plan in the same state may cover GLP-1 for the employee of one company and not the next, because the employer chose different formulary tiers. Express Scripts and CVS Caremark, the two largest pharmacy benefit managers, each offer multiple GLP-1 coverage configurations. The employer picks the configuration. The PBM administers what the employer paid for.

The result is that “my insurance covers Wegovy” is an incomplete sentence. The complete version is “my employer’s specific contract with my insurer’s PBM covers Wegovy at tier 2 with a $50 copay after prior authorization.” Two coworkers at different companies on the same insurance brand can get different answers.

ACA marketplace plans add another wrinkle. Most marketplace plans in most states do not cover GLP-1 for obesity, though many cover for diabetes. Coverage of the cardiovascular indication after the 2024 FDA expansion has been slower than the Medicare adoption.

How to find out what your plan actually covers before the telehealth consultation.

Three practical moves, in order.

First, pull up your plan’s formulary through your member portal. Search for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro by brand name. Note the tier and any prior authorization requirements listed next to each one.

Second, call the member services number on your card. Ask specifically: is this drug covered for weight management indication, and what is required for prior authorization? The phrase “for weight management” matters. Coverage for type 2 diabetes is often present even when obesity coverage is not, and a vague answer that the drug “is on formulary” does not distinguish.

Third, if the answer is no, ask what the appeal pathway looks like and what documentation would change the outcome. Some plans cover for cardiovascular risk reduction with the right documentation even when obesity coverage is excluded. The 2024 FDA label expansion is still working through plan policies.

For provider selection, Epioneum’s methodology scores insurance compatibility as part of how providers handle the brand-name pathway. Some telehealth programs are built around insurance billing and prior authorization. Others operate strictly cash-pay and never touch a formulary. The choice is consequential, and the program’s transparency about which lane they run in is the scoreable part.

What we don’t know yet

The CMS rule proposed in November 2024 to expand anti-obesity medication coverage through Medicare and Medicaid was declined for the CY2026 final rule on April 4, 2025. Whether the agency revisits the question in future rulemaking, and on what timeline, has not been signaled. The state Medicaid coverage list shifts faster than survey data tracks — between October 2025 and January 2026, four states dropped coverage and a fifth (North Carolina) dropped and reinstated within the same quarter. KFF’s quarterly updates are the most reliable source, but they lag actual state policy decisions by weeks. State employee plan changes happen mid-fiscal-year if pharmacy budgets blow through projection, the way North Carolina’s did.

The cardiovascular indication is still new enough that plan-by-plan interpretation of “established cardiovascular disease” varies widely. Some plans require a prior MI or stroke. Others accept documented coronary artery disease imaging. The phrase has not settled.

What tirzepatide’s expanding label does to the math is open. The FDA approved Zepbound for obstructive sleep apnea in late 2024. Additional indications for cardiovascular and renal outcomes are in trials. Each new approved indication is a new ICD-10 code that could open a coverage door the obesity-only code keeps closed.

The structural picture is the part that does not change. The country has not decided whether obesity is a chronic disease that insurance should cover or a lifestyle issue patients should pay for out of pocket. Wegovy and Zepbound force the question because they actually work, at a price point that breaks public budgets when coverage is broad and individual budgets when coverage is denied.

Until that question is settled at the federal level, your zip code will keep mattering more than your BMI.

This guide is informational only. It is not medical advice and is not legal or insurance advice. State and federal coverage rules change frequently; verify current plan policy with your member services line before relying on any specific coverage outcome. Spot a factual error? corrections@epioneum.com.